Jefferies is out with its report today on Amarin AMRN, maintaining Buy.
In a note to clients, Jefferies writes, "We had an opportunity to spend time with AMRN senior management to discuss potential scenarios for a pharma partnership or acquisition, AMR101 regulatory filings, and the CV outcomes study required to file for an ANCHOR indication. We continue to believe in a multi-billion market opportunity for AMR101, and AMRN remains one of our top biotech picks."
At the time of posting, shares of AMRN were trading pre-market at $19.84, up 1.74% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in